Novartis Mellaril
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Thioridazine labeling is revised to add black box warning on QTc prolongation and to shift the drug to second-line use in patients refractory or intolerant to other anti-psychotics. The warning states that Mellaril has been shown to "prolong the QTc interval in a dose-related manner, and drugs with this potential, including Mellaril, have been associated with torsade de pointes-type arrhythmia and death," according to a July 7 Novartis "Dear Doctor" letter. The agent also added contraindications for use with several drugs, including fluvoxamine, propranolol, pindolol, fluoxetine and paroxetine. Labeling changes are based on FDA review of three published studie
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.